Citation: Zhenxing Gao, Min Peng, Liang Chen, Xiaowen Yang, Huan Li, Run Shi, Guiru Wu, Lili Cai, Qibin Song, Chaoyang Li. Prion Protein Protects Cancer Cells against Endoplasmic Reticulum Stress Induced Apoptosis .VIROLOGICA SINICA, 2019, 34(2) : 222-234.

Prion Protein Protects Cancer Cells against Endoplasmic Reticulum Stress Induced Apoptosis

  • Received Date: 09 November 2018
    Accepted Date: 28 February 2019
    Published Date: 24 April 2019
    Available online: 01 April 2019
  • Unfolded protein response (UPR) is an adaptive reaction for cells to reduce endoplasmic reticulum (ER) stress. In many types of cancers, such as lung cancer and pancreatic cancer, cancer cells may harness ER stress to facilitate their survival and growth. Prion protein (PrP) is a glycosylated cell surface protein that has been shown to be up-regulated in many cancer cells. Since PrP is a protein prone to misfolding, ER stress can result in under-glycosylated PrP, which in turn may activate ER stress. To assess whether ER stress leads to the production of under-glycosylated PrP and whether underglycosylated PrP may contribute to ER stress thus leading to cancer cell apoptosis, we treated different cancer cells with brefeldin A (BFA), thapsigargin (Thps), and tunicamycin (TM). We found that although BFA, Thps, and TM treatment activated UPR, only ATF4 was consistently activated by these reagents, but not other branches of ER stress. However, the canonical PERK-eIF2α-ATF4 did not account for the observed activation of ATF4 in lung cancer cells. In addition, BFA, but neither Thps nor TM, significantly stimulated the expression of cytosolic PrP. Finally, we found that the levels of PrP contributed to anti-apoptosis activity of BFA-induced cancer cell death. Thus, the pathway of BFA-induced persistent ER stress may be targeted for lung and pancreatic cancer treatment.

  • 加载中
  • 222_ESM.pdf
    1. Bendheim PE, Brown HR, Rudelli RD, Scala LJ, Goller NL, Wen GY, Kascsak RJ, Cashman NR, Bolton DC. 1992. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology, 42:149-156
        doi: 10.1212/WNL.42.1.149

    2. Bobrovnikova-Marjon E, Pytel D, Riese MJ, Vaites LP, Singh N, Koretzky GA, Witze ES, Diehl JA. 2012. PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation. Mol Cell Biol, 32:2268-2278
        doi: 10.1128/MCB.00063-12

    3. Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A. 2001. Prion protein protects human neurons against Bax-mediated apoptosis. J Biol Chem, 276:39145-39149
        doi: 10.1074/jbc.C100443200

    4. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-Schaeffer W, Giese A, Westaway D, Kretzschmar H. 1997. The cellular prion protein binds copper in vivo. Nature, 390:684-687
        doi: 10.1038/37783

    5. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. 2016. Cancer statistics in China, 2015. CA Cancer J Clin, 66:115-132
        doi: 10.3322/caac.21338

    6. Clarke HJ, Chambers JE, Liniker E, Marciniak SJ. 2014. Endoplasmic reticulum stress in malignancy. Cancer Cell, 25:563-573
        doi: 10.1016/j.ccr.2014.03.015

    7. Corazzari M, Gagliardi M, Fimia GM, Piacentini M. 2017. Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell Fate. Front Oncol, 7:78
        doi: 10.3389/fonc.2017.00078

    8. Cullinan SB, Diehl JA. 2004. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem, 279:20108-20117
        doi: 10.1074/jbc.M314219200

    9. DenBoer LM, Hardy-Smith PW, Hogan MR, Cockram GP, Audas TE, Lu R. 2005. Luman is capable of binding and activating transcription from the unfolded protein response element. Biochem Biophys Res Commun, 331:113-119
        doi: 10.1016/j.bbrc.2005.03.141

    10. Dery MA, LeBlanc AC. 2017. Luman contributes to brefeldin A-induced prion protein gene expression by interacting with the ERSE26 element. Sci Rep, 7:42285
        doi: 10.1038/srep42285

    11. Dery MA, Jodoin J, Ursini-Siegel J, Aleynikova O, Ferrario C, Hassan S, Basik M, LeBlanc AC. 2013. Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer. Breast Cancer Res 15:R22
        doi: 10.1186/bcr3398

    12. Diarra-Mehrpour M, Arrabal S, Jalil A, Pinson X, Gaudin C, Pietu G, Pitaval A, Ripoche H, Eloit M, Dormont D, Chouaib S. 2004. Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. Cancer Res, 64:719-727
        doi: 10.1158/0008-5472.CAN-03-1735

    13. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France

    14. Han T, Tian K, Pan H, Liu Y, Xu F, Li Z, Uchita T, Gao M, Hua H, Li D. 2018. Novel hybrids of brefeldin A and nitrogen mustards with improved antiproliferative selectivity: design, synthesis and antitumor biological evaluation. Eur J Med Chem, 150:53-63
        doi: 10.1016/j.ejmech.2018.02.088

    15. Harding HP, Zhang Y, Ron D. 1999. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature, 397:271-274
        doi: 10.1038/16729

    16. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. 2000. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell, 6:1099-1108
        doi: 10.1016/S1097-2765(00)00108-8

    17. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK. 2008. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst, 100:1672-1694
        doi: 10.1093/jnci/djn389

    18. Jin T, Gu Y, Zanusso G, Sy M, Kumar A, Cohen M, Gambetti P, Singh N. 2000. The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome. J Biol Chem, 275:38699-38704
        doi: 10.1074/jbc.M005543200

    19. Kaufman RJ. 1999. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev, 13:1211-1233
        doi: 10.1101/gad.13.10.1211

    20. Kuwahara C, Takeuchi AM, Nishimura T, Haraguchi K, Kubosaki A, Matsumoto Y, Saeki K, Matsumoto Y, Yokoyama T, Itohara S, Onodera T. 1999. Prions prevent neuronal cell-line death. Nature, 400:225-226
        doi: 10.1038/22241

    21. Lawson VA, Collins SJ, Masters CL, Hill AF. 2005. Prion protein glycosylation. J Neurochem, 93:793-801
        doi: 10.1111/jnc.2005.93.issue-4

    22. Lee AS, Hendershot LM. 2006. ER stress and cancer. Cancer Biol Ther, 5:721-722
        doi: 10.4161/cbt.5.7.3120

    23. Li C, Yu S, Nakamura F, Yin S, Xu J, Petrolla AA, Singh N, Tartakoff A, Abbott DW, Xin W, Sy MS. 2009. Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J Clin Invest, 119:2725-2736
        doi: 10.1172/JCI39542

    24. Ma J, Wollmann R, Lindquist S. 2002. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science, 298:1781-1785
        doi: 10.1126/science.1073725

    25. Maisonneuve P, Lowenfels AB. 2010. Epidemiology of pancreatic cancer: an update. Dig Dis, 28:645-656
        doi: 10.1159/000320068

    26. Meslin F, Hamai A, Gao P, Jalil A, Cahuzac N, Chouaib S, Mehrpour M. 2007. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death. Cancer Res, 67:10910-10919
        doi: 10.1158/0008-5472.CAN-07-0512

    27. Misumi Y, Misumi Y, Miki K, Takatsuki A, Tamura G, Ikehara Y. 1986. Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J Biol Chem, 261:11398-11403

    28. Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, Kellermann O. 2000. Signal transduction through prion protein. Science, 289:1925-1928
        doi: 10.1126/science.289.5486.1925

    29. Nunziante M, Ackermann K, Dietrich K, Wolf H, Gadtke L, Gilch S, Vorberg I, Groschup M, Schatzl HM. 2011. Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein. J Biol Chem, 286:33942-33953
        doi: 10.1074/jbc.M111.272617

    30. Orsi A, Fioriti L, Chiesa R, Sitia R. 2006. Conditions of endoplasmic reticulum stress favor the accumulation of cytosolic prion protein. J Biol Chem, 281:30431-30438
        doi: 10.1074/jbc.M605320200

    31. Paitel E, Sunyach C, Alves da Costa C, Bourdon JC, Vincent B, Checler F. 2004. Primary cultured neurons devoid of cellular prion display lower responsiveness to staurosporine through the control of p53 at both transcriptional and post-transcriptional levels. J Biol Chem, 279:612-618
        doi: 10.1074/jbc.M310453200

    32. Prusiner SB. 1998. Prions. Proc Natl Acad Sci U S A, 95:13363-13383
        doi: 10.1073/pnas.95.23.13363

    33. Rambold AS, Miesbauer M, Rapaport D, Bartke T, Baier M, Winklhofer KF, Tatzelt J. 2006. Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. Mol Biol Cell, 17:3356-3368
        doi: 10.1091/mbc.e06-01-0083

    34. Rao RV, Bredesen DE. 2004. Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol, 16:653-662
        doi: 10.1016/

    35. Rogers M, Taraboulos A, Scott M, Groth D, Prusiner SB. 1990. Intracellular accumulation of the cellular prion protein after mutagenesis of its Asn-linked glycosylation sites. Glycobiology, 1:101-109
        doi: 10.1093/glycob/1.1.101

    36. Roucou X, Giannopoulos PN, Zhang Y, Jodoin J, Goodyer CG, LeBlanc A. 2005. Cellular prion protein inhibits proapoptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells. Cell Death Differ, 12:783-795
        doi: 10.1038/sj.cdd.4401629

    37. Shi Y, Vattem KM, Sood R, An J, Liang J, Stramm L, Wek RC. 1998. Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol, 18:7499-7509
        doi: 10.1128/MCB.18.12.7499

    38. Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA Cancer J Clin, 66:7-30
        doi: 10.3322/caac.21332

    39. Stahl N, Borchelt DR, Hsiao K, Prusiner SB. 1987. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell, 51:229-240
        doi: 10.1016/0092-8674(87)90150-4

    40. Takatsuki Akira KK, Gakuzo Tamura (1975) Inhibition of biosynthesis of polyisoprenol sugars in chick embryo microsomes by Tunicamycin. Agric Biol Chem, 39:2089-2091

    41. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP. 1990. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc Natl Acad Sci USA, 87:2466-2470
        doi: 10.1073/pnas.87.7.2466

    42. Vincent B, Sunyach C, Orzechowski HD, St George-Hyslop P, Checler F. 2009. p53-Dependent transcriptional control of cellular prion by presenilins. J Neurosci, 29:6752-6760
        doi: 10.1523/JNEUROSCI.0789-09.2009

    43. Wang M, Kaufman RJ. 2014. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer, 14:581-597
        doi: 10.1038/nrc3800

    44. Wang X, Dong CF, Shi Q, Shi S, Wang GR, Lei YJ, Xu K, An R, Chen JM, Jiang HY, Tian C, Gao C, Zhao YJ, Han J, Dong XP. 2009. Cytosolic prion protein induces apoptosis in human neuronal cell SH-SY5Y via mitochondrial disruption pathway. BMB Rep, 42:444-449
        doi: 10.5483/BMBRep.2009.42.7.444

    45. Wu GR, Mu TC, Gao ZX, Wang J, Sy MS, Li CY. 2017. Prion protein is required for tumor necrosis factor alpha (TNFalpha)-triggered nuclear factor kappaB (NF-kappaB) signaling and cytokine production. J Biol Chem, 292:18747-18759
        doi: 10.1074/jbc.M117.787283

    46. Yang L, Zhang Y, Hu L, Zhu Y, Sy MS, Li C. 2014a. A panel of monoclonal antibodies against the prion protein proves that there is no prion protein in human pancreatic ductal epithelial cells. Virol Sin, 29:228-236
        doi: 10.1007/s12250-014-3480-4

    47. Yang X, Zhang Y, Zhang L, He T, Zhang J, Li C. 2014b. Prion protein and cancers. Acta Biochim Biophys Sin (Shanghai), 46:431-440
        doi: 10.1093/abbs/gmu019

    48. Yang L, Gao Z, Hu L, Wu G, Yang X, Zhang L, Zhu Y, Wong BS, Xin W, Sy MS, Li C. 2016. Glycosylphosphatidylinositol anchor modification machinery deficiency is responsible for the formation of pro-prion protein (PrP) in BxPC-3 protein and increases cancer cell motility. J Biol Chem, 291:3905-3917
        doi: 10.1074/jbc.M115.705830

    49. Ye J, Rawson RB, Komuro R, Chen X, Dave UP, Prywes R, Brown MS, Goldstein JL. 2000. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell, 6:1355-1364
        doi: 10.1016/S1097-2765(00)00133-7

    50. Zhang H, Gao S, Pei R, Chen X, Li C. 2017. Hepatitis c virus-induced prion protein expression facilitates hepatitis c virus replication. Virol Sin, 32:503-510
        doi: 10.1007/s12250-017-4039-y

    51. Zhang W, Hietakangas V, Wee S, Lim SC, Gunaratne J, Cohen SM. 2013. ER stress potentiates insulin resistance through PERK-mediated FOXO phosphorylation. Genes Dev, 27:441-449
        doi: 10.1101/gad.201731.112

    52. Zhou L, Shang Y, Liu C, Li J, Hu H, Liang C, Han Y, Zhang W, Liang J, Wu K. 2014. Overexpression of PrPc, combined with MGr1-Ag/37LRP, is predictive of poor prognosis in gastric cancer. Int J Cancer 135:2329-2337
        doi: 10.1002/ijc.28883

  • 加载中

Figures(6) / Tables(1)

Article Metrics

Article views(3799) PDF downloads(30) Cited by()

Proportional views

    Prion Protein Protects Cancer Cells against Endoplasmic Reticulum Stress Induced Apoptosis

    • 1. State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
    • 2. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, China
    • 3. Department of the First Abdominal Surgery, Jiangxi Tumor Hospital, Nanchang 330029, China

    Abstract: Unfolded protein response (UPR) is an adaptive reaction for cells to reduce endoplasmic reticulum (ER) stress. In many types of cancers, such as lung cancer and pancreatic cancer, cancer cells may harness ER stress to facilitate their survival and growth. Prion protein (PrP) is a glycosylated cell surface protein that has been shown to be up-regulated in many cancer cells. Since PrP is a protein prone to misfolding, ER stress can result in under-glycosylated PrP, which in turn may activate ER stress. To assess whether ER stress leads to the production of under-glycosylated PrP and whether underglycosylated PrP may contribute to ER stress thus leading to cancer cell apoptosis, we treated different cancer cells with brefeldin A (BFA), thapsigargin (Thps), and tunicamycin (TM). We found that although BFA, Thps, and TM treatment activated UPR, only ATF4 was consistently activated by these reagents, but not other branches of ER stress. However, the canonical PERK-eIF2α-ATF4 did not account for the observed activation of ATF4 in lung cancer cells. In addition, BFA, but neither Thps nor TM, significantly stimulated the expression of cytosolic PrP. Finally, we found that the levels of PrP contributed to anti-apoptosis activity of BFA-induced cancer cell death. Thus, the pathway of BFA-induced persistent ER stress may be targeted for lung and pancreatic cancer treatment.

    • Lung cancer and pancreatic ductal adenocarcinoma (PDAC) are two of the most deadly malignant tumors worldwide (Ferlay et al. 2013; Siegel et al. 2016). The fiveyear survival rate was 6% for both tumors owing to the lack of diagnostic markers or appropriate screening tests, and drug resistance to cancer treatment (Jemal et al. 2008; Maisonneuve and Lowenfels 2010). Most importantly, cancer burden including lung cancer and PDAC in China will continue to increase in the next decades (Chen et al. 2016). Thus, understanding how cellular factors contribute to the tumorigenesis of lung cancer and PDAC is very important for the development of a treatment approach.

      Cellular prion protein (PrP) is a glycosylphosphatidylinositol (GPI)—anchored protein highly expressed in neuron cells of the central nervous system. PrP has been attributed to cell adhesion, anti-apoptosis, migration, signaling, viral replication, immune modulation, and cell differentiation (Brown et al. 1997; Kuwahara et al. 1999; Mouillet-Richard et al. 2000; Bounhar et al. 2001; Paitel et al. 2004; Wu et al. 2017; Zhang et al. 2017). However, the physiological function of this protein remains elusive, although it is known to be essential for transmissible spongiform encephalopathy (Prusiner 1998). The expression of PrP is undetectable in normal pancreatic ductal cells or hepatocytes (Bendheim et al. 1992; Li et al. 2009; Yang et al. 2014a). However, in some solid tumors, such as PDAC, oral squamous cell carcinoma, colon cancer, breast cancer, gastric cancer, melanoma, and glioma, the expression level of PrP is up-regulated (Yang et al. 2014b). More importantly, expression of PrP has been reported as a biomarker for poor prognosis for PDAC, breast cancer, and gastric cancer (Li et al. 2009; Dery et al. 2013; Zhou et al. 2014).

      Accumulation of misfolded or unfolded proteins in the endoplasmic reticulum (ER) causes ER stress, which may activate an unfolded protein response (UPR). At least three sensors of ER stress have been identified: (1) inositolrequiring protein 1 (IRE1); (2) pancreatic-like ER kinase like- kinase (PERK); and (3) activating transcription factor 6 (ATF6). IRE1α is activated upon dimerization to produce an active transcription factor, spliced X-box binding protein 1 (XBP-1s), which controls, for example, the transcription of gene encoding proteins for ER-associated degradation (ERAD) and phospholipid synthesis (Rao and Bredesen 2004). PERK phosphorylates the initiation factor eukaryotic translation initiator factor 2α (eIF2α), nuclear factor erythroid 2-related factor 2 (NRF2), forkhead box O, and diacylglycerol (Shi et al. 1998; Harding et al. 1999; Cullinan and Diehl 2004; Bobrovnikova-Marjon et al. 2012; Zhang et al. 2013). Phosphorylated eIF2α may then result in the modulation of autophagy, apoptosis, amino acid metabolism, or antioxidant responses. Under ER stress, ATF6 binds coat protein Ⅱ complex to enter the Golgi apparatus where it is cleaved by site 1 protease (S1P) and site 2 protease (S2P) to release the cytosolic domain fragment ATF6f (Ye et al. 2000). ATF6f further fine tunes the genes involved in ERAD and XBP-1.

      Several chemicals, such as tunicamycin (TM), thapsigargin (Thps), and brefeldin A (BFA) have been used extensively to induce ER stress in cell models. These agents appear to induce UPR via different mechanisms as TM is a potent inhibitor of GlcNAc phosphotransferase to prevent glycosylation of glycoprotein; Thps depletes calcium in ER; whereas BFA impedes protein transport from the ER to the Golgi apparatus (Takatsuki Akira and Gakuzo 1975; Misumi et al. 1986; Thastrup et al. 1990).

      Due to their increased metabolic requirements, tumor cells engage UPR to promote their growth demand, survival, and metastasis (Corazzari et al. 2017). Lung cancer and PDAC cells are highly secretory and prone to constitutive UPR activation and thus may harness ER stress for their own privilege (Lee and Hendershot 2006; Wang and Kaufman 2014). However, the relationship between PrP expression and ER stress in cancer cells remains obscure. In HeLa and N2a cells, ER stress reduces total PrP level (Orsi et al. 2006; Nunziante et al. 2011). On the contrary, up-regulation of PrP was observed with ER stress in breast cancer (Dery et al. 2013). Therefore, we hypothesize that the interplay between PrP and ER stress may be cell-context dependent.

      PrP is known to be important in tumorigenesis, therefore we aimed to investigate the role PrP plays in cancer cells during ER stress to better understand the action of two of the deadliest cancers worldwide, lung cancer and PDAC.

    • PDAC cell line BxPC-3 was purchased from American Type Culture Collection (ATCC). PRNP null BxPC-3 cells were generated as previously described (Yang et al. 2016). Nonsmall-cell lung carcinoma cell lines A549, H157, H1299, and SPC-A1 were obtained from China Center for Type Culture Collection. These cells were cultured in RPMI1640 medium (31800-022, Gibco, Grand Island, NY, USA) supplemented with 10% FBS (10099-141, Gibco), 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 3 g/L HEPES (V900477, SigmaAldrich, Darmstadt, Germany), 1 mmol/L sodium pyruvate (11360-070, Gibco), 100 U/mL of antibiotic penicillin– streptomycin solution (03-031-1, Biological Industries, Kibbutz Beit-Haemek, Israel) in a humidified atmosphere containing 5% CO2.

    • Anti-PrP specific monoclonal antibody (4H2) was generated in our laboratory as previously described (Yang et al. 2014a). Anti-β-actin mouse monoclonal antibody (KM9001) was purchased from Tianjin Sungene Biotech (Tianjin, China). PARP-1 antibody (9542), ATF4 antibody (11815), phospho-eIF2a (p-eIF2α, 3398), eIF2α (5324), p53 (9282), caspase-3 (9665), and cleaved caspase-3 (9661) were purchased from Cell Signaling Technology (Danvers, MA, USA). Glucose response protein 78 or binding immunoglobulin protein (Grp78/BiP) antibody (11587-1-AP) was purchased from Proteintech (Wuhan, Hubei, China). Anti-XBP-1 antibody (ab37152) was purchased from Abcam (Cambridge, MA, USA). Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (H+L) antibody (AS003) and HRP-conjugated goat anti-rabbit IgG antibody (AS014) were purchased from Abclonal (Wuhan, China). Alexa Fluor 488 conjugated goat antirabbit IgG (H+L) secondary antibody (R37116) and Alexa Fluor 555 conjugated goat anti-mouse IgG (H+L) secondary antibody (A32727) were purchased from Invitrogen (Eugene, OR, USA). 4', 6-diamidine-2'-phenylindole dihydrochloride (DAPI) (10236276001) was purchased from Roche (Mannheim, Germany). BFA (S1536) was purchased from Beyotime (Shanghai, China). Dimethyl sulfoxide (DMSO, D2650), Thps (T9033) and TM (T7765) were purchased from Sigma-Aldrich. Other reagents reported in the paper were purchased from Amresco (Solon, Ohio, USA). All reagents purchased from commercial sources were used according to the suppliers' recommendations.

    • Cells were seeded in 12-well plates overnight. When cell confluence reached 70%–80%, the medium was changed with fresh medium supplemented with the indicated concentrations of BFA, Thps and TM. Dimethyl sulfoxide (DMSO) was used as vehicle control. After 24 h, the cells were rinsed twice with ice cold phosphate buffered saline (PBS). Cell lysate was made in cell lysis buffer (20 mmol/L Tris–HCl (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L β-glycerol phosphate, 1 mmol/L Na3VO4); and 1 mmol/L PMSF and protease inhibitor cocktail (04693116001, Roche) were added freshly. Protein concentration was determined by Bio-Rad Protein Assay Kit Ⅱ (5000002, Hercules, CA, USA).

    • An amount of 20 μg of proteins per sample was combined with 1 μL 10 × glycoprotein denaturing buffer and deionized water to make a 10 μL reaction volume on ice. The sample was then boiled for 10 min. Then, 2 μL 10 × G7 buffer, 2 μL 10% NP40, 5 μL deionized water and 1 μL PNGase F (P0704, New England Biolabs, Ipswich, MA, USA) were added to make a total of 20 μL reaction mixture. PNGase F treated samples were then subjected for immunoblotting.

    • Samples were mixed with 4 × sample reducing buffer (40% glycerol (V/V), 250 mmol/L Tris-HCl pH 6.8 (V/V), 8% sodium dodecyl sulfate (SDS, W/V), 0.04% bromophenol blue (W/V), and 20% β-mercaptoethanol (V/V)). The samples were then heated at 100 ℃ in a heat block for 5 min. Samples were separated on a 10% SDS–polyacrylamide gel electrophoresis (PAGE) gel, and then transferred to nitrocellulose membrane. After blocking in 3% bovine serum albumin (BSA) in TBST (137 mmol/L NaCl, 20 mmol/L Tris, 0.1% Tween 20, pH7.6), the blots were probed by the indicated primary antibodies at the indicated concentrations. Bound primary antibody was further probed with HRP-conjugated goat anti-mouse IgG secondary antibody (1:10, 000) or HRP-conjugated goat anti-rabbit IgG secondary antibody (1:10, 000).

    • Total RNA was isolated from cultured cells using an RNA purification kit (TR01-150, GeneMark, Taichung, Taiwan). An amount of 0.8 μg RNA was reverse transcribed to cDNA by using a PrimeScriptTM RT reagent kit (RR047A, TaKaRa, Shiga, Japan). Quantitative PCR (qPCR) was carried out on a Bio-Rad real-time PCR instrument (CFX Connect Real-Time PCR Detection System, Bio-Rad). Each reaction volume of 20 μL contained cDNA templates, primer pairs, and SYBR Green Supermix (170-8882AP, Bio-Rad). Amplification occurred after initial denaturation at 95 ℃ for 3 min, followed by 40 cycles of 95 ℃ for 15 s, 60 ℃ for 30 s, and 72 ℃ for 20 s. β-ACTIN was used as a reference gene. Gene-specific primers used for qPCR are listed in Supplementary Table S1.

    • Cells were seeded into poly-D-lysine-coated glass bottom petri dishes overnight. To detect the cell surface PrP, cells were washed with ice cold PBS three times then the cells were incubated with 5 μg/mL 4H2 or isotype control mouse IgG1 for 1 h at room temperature. Bound antibodies were probed with AlexaFluor 555 conjugated goat antimouse IgG. DAPI was used to counterstain the nuclei. Images were taken with Olympus inverted microscopy (Tokyo, Japan). To detect the co-immunostaining of PrP and BiP, cells were prepared as above. After 24 h BFA treatment, the cells were washed with ice cold PBS three times. Cells were then fixed in 4% paraformaldehyde for 15 min at room temperature and washed with PBS three times. After blocking for 1 h (1% BSA, 10% goat serum diluted in PBSTT (0.1% tween 20, 0.3% Triton X-100)), 4H2 (10 μg/mL) and BiP (1:100) antibody in blocking buffer were applied for 1 h. Bound antibodies were probed with Alexa Fluor 555 conjugated goat anti-mouse IgG and Alexa Fluor 488 conjugated goat anti-rabbit IgG. Images were taken with A1 MP+ multiphoton confocal microscope (IMA101065ALS, Nikon, Japan) after being counterstained with DAPI and immersed with antifade.

      To detect cell apoptosis, we used an Annexin V-FITC cell apoptosis kit (C1062, Beyotime) for in situ immunostaining and flow cytometry analysis. Briefly, for in situ immunostaining, cells were seeded in 12-well plates overnight. After 16 h, the medium were changed with fresh medium supplemented with the indicated concentrations of BFA or DMSO for an additional 24 h. Cells were then washed twice with ice cold PBS, and then incubated with 210 μL of apoptosis detection buffer (195 μL Annexin V-FITC binding buffer, 5 μL Annexin V-FITC, 10 μL propidium iodide) for 15 min at room temperature in the dark. Images were taken with Olympus inverted microscopy.

    • To quantify cell apoptosis with flow cytometry, cells were seeded in 6-well plates overnight. After 16 h, the medium were replaced with fresh medium supplemented with indicated concentration of BFA or DMSO for an additional 24 h. The cells were then scraped and digested with trypsin/EDTA. Digested cells were centrifuged at 1000 ×g for 5 min at 4 ℃. After washing with PBS once, cells were transferred in a 1.5 mL tube and were further stained with 5 μL of Annexin V-FITC and 10 μL of PI in 195 μL Annexin V-FITC binding buffer for 15 min at room temperature in the dark. The samples were analyzed in a FACS AriaIII flow cytometer (BD Biosciences, NJ, USA).

    • Data are expressed as mean ± SEM (standard error of the mean). Statistical analysis was performed using 2-tailed student's t test. A value of P < 0.05 was considered statistically significant. The following levels of statistical significance were used: *P < 0.05; **P < 0.01; ***P < 0.001.

    • PrP is expressed at low levels in normal human lung tissue (The Human Protein Atlas). Whether lung cancer cell lines express PrP has never been studied in detail. Therefore, to investigate if lung cancer cell lines express PrP, we blotted cell lysates from A549, H157, SPC-A1, H1299, and BxPC-3 cells with PrP-specific mAb 4H2 and found that A549, H157, H1299 and BxPC-3 cells expressed PrP, while only SPC-A1 did not (Fig. 1A). Confocal immunofluorescence staining confirmed that A549, H157, H1299, and BxPC-3 cells expressed PrP and most of the PrP was cell surface bound (Fig. 1B). Therefore, most lung cancer cell lines express PrP.

      Figure 1.  Cancer cells express different levels of PrP. A Immunoblotting with PrP specific mAb 4H2 showed that A549, H157, H1299, and BxPC-3 cells expressed PrP. A residual level of PrP was detected in SPC-A1 cell lysate. PRNP null BxPC-3 cells were used as negative control. β-actin was used a loading control. B Confocal immunofluorescence staining with 4H2 revealed that A549, H157, H1299, and BxPC-3 cells expressed PrP, and most PrP was cell surface bound. On the contrary, no signal of PrP was detected in SPC-A1 and PRNP null BxPC-3 cells. Nuclei were counter stained with DAPI. The experiments were repeated three times with similar results

    • The promoter region of PrP has been reported to have XBP-1, ATF4, and ATF6 binding elements. Treatment of breast cancer cell lines with chemicals inducing ER stress results in PrP expression (Dery et al. 2013). To investigate if BFA, Thps, and TM treatment of BxPC-3, SPC-A1, and H1299 up-regulated UPR response, we treated these cells in vitro with BFA, Thps, or TM for 24 h. We found that BFA treatment of BxPC-3, SPC-A1, and H1299 cells significantly enhanced mRNA levels of ATF4 and XBP-1 (Fig. 2A). In addition, Thps and TM also enhanced mRNA of ATF4 and XBP-1 in SPC-A1 and H1299 cells but at significantly lower levels compared to the effects of BFA (Fig. 2A). On the contrary, Thps, but not TM, activated XBP-1 mRNA level in BxPC-3 cells (Fig. 2A). These results imply that transcriptional factors such as ATF4 and XBP-1 may be activated in cancer cells by BFA.

      Figure 2.  ER stress enhances ATF4 and XBP-1 mRNA levels in BxPC-3, SPC-A1 and H1299 cells. A ER stress was induced by culturing cells in the presence of BFA, Thps, or TM for 24 h. DMSO was used as vehicle control (Ctrl). Expression of ATF4 and XBP-1 mRNA levels was quantified by qPCR and normalized by β-ACTIN. BFA, Thps, or TM activated significant expression of ATF4 and XBP-1 transcripts in SPC-A1 and H1299 cells. However, only BFA induced significant ATF4 expression in BxPC-3 cells. In addition, significant expression of XBP-1 was induced by BFA and Thps in BxPC-3 cells. Statistical significance was indicated as: *P < 0.05; **P < 0.01; ***P < 0.001. B BFA activates PrP expression via ER stress. BFA, Thps, and TM induced expression of BiP. BFA reduced p-eIF2α expression in BxPC-1 cells but not in SPC-A1 and H1299 cells. However, in all tested cells, eIF2α levels were not altered by the treatment. BFA, Thps, and TM activated ATF4 levels in all tested cancer cells. XBP-1 was constitutively activated in all tested cancer cells. Increased PrP levels were detected in all tested cancer cells by BFA but neither Thps nor TM treatment. PrP was indicated by *. Some proteins reacting to 4H2 were non-specific. The experiments were repeated three times

      To confirm the mRNA findings, we blotted those cell lysates with antibodies specific for p-eIF2α, total eIF2α, ATF4, and XBP-1, respectively, to identify which pathway(s) was activated. P-eIF2α has a translational inhibition effect on most proteins; however, it enhances the translation of ATF4. We found that in BxPC-3 cells, BFA, Thps, and TM treatment reduced the level of p-eIF2α (Fig. 2B). However, in H1299 cells, BFA, Thps, and TM treatment increased p-eIF2α level, whereas p-eIF2α was not detected in SPC-A1 cells (Fig. 2B). In contrast to p-eIF2α, when cell lysates were blotted with antibody specific for ATF4, we found that ATF4 was significantly up-regulated at 24 h post BFA, Thps, and TM treatment, although Thps and TM were not as efficient as BFA to activate ATF4 in those cells (Fig. 2B). Therefore the canonical PERK-eIF2α-ATF4 might occur only in H1299 cells but not in BxPC-3 and SPC-A1 cells.

      Activated XBP-1 (XBP-1s) has an apparent molecular weight of 40 kDa, whereas the non-spliced form of XBP-1 (XBP-1u) is approximately 29 kDa. When blotted with anti-XBP-1 specific antibody, we found that all tested cancer cells expressed an active form of XBP-1s, even in the absence of BFA, Thps, and TM treatment (Fig. 2B). However, lung cancer cells SPC-A1 and H1299 expressed higher levels of XBP-1s than PDAC cells BxPC-3. These results suggested that XBP-1s is constitutively activated in those cancer cells.

      Since up-regulation of BiP could be a marker for UPR (Kaufman 1999), we blotted the cell lysates from treated cells with anti-BiP specific antibody to investigate whether UPR occurred in those cells. We found that all treated cells showed significantly enhanced BiP levels (Fig. 2B). These results suggest that indeed UPR was induced in those cells by different reagents, albeit at different levels. Interestingly, when low-expressing PrP SPC-A1 cells were treated with UPR stimulants, they expressed higher levels of both ATF4 and BiP compared to high-expressing PrP H1299 and BxPC-3 cells which were treated the same way. Therefore, cells with lower PrP levels might respond better to ER stress than cells with higher PrP levels. In other words, PrP is a negative regulator of ER stress.

    • We then investigated whether ER stress induced PrP expression. We first blotted cell lysates with 4H2 and found significant up-regulation of PrP at 24 h after BFA treatment for all tested cells (Fig. 2B, indicated by *). Similarly, significantly more PrP expression was observed in H1299 cells than in SPC-A1 cells (Fig. 2B, indicated by *). In contrast to BFA treatment, Thps and TM treatment did not induce, and in some cases reduced PrP expression at protein levels in these cancer cells (Fig. 2B). More importantly, the expression pattern of PrP was different in BxPC-3 cells as compared to PrP in lung cancer cells (Fig. 2B). The reason for this difference is unknown. To further confirm that the up-regulated expression of PrP is due to ER stress, which stimulated the ATF4 transcriptional factor to transcribe PRNP, we performed qPCR to quantify PRNP mRNA levels after treatment. In BxPC-3 and SPC-A1 cells, BFA, Thps, and TM activated significant PRNP transcription. In contrast, in H1299 cells, BFA and Thps, but not TM, treatment activated significant PRNP transcripts (Fig. 3). Thus, BFA and Thps seemed to be able to induce PRNP transcription via ER stress in all tested cells.

      Figure 3.  PRNP transcripts were significantly elevated in SPC-A1 and BxPC-3 cells by BFA treatment. BFA, Thps, and TM treatment significantly enhanced PRNP levels in BxPC-3 and SPC-A1 cells. However, BFA and Thps but not TM significantly activated PRNP expression in H1299 cells. DMSO was used as vehicle control (Ctrl). The experiments were repeated three times. Statistical analyses were indicated as: *P < 0.05; **P < 0.01; ***P < 0.001

    • In addition to motifs binding XBP-1, ATF4, and ATF6, the promoter region of PRNP contains the motif for p53 binding (Vincent et al. 2009). To exclude the possibility that BFA-induced PrP expression was transcribed by p53, we treated BxPC-3, H1299, and SPC-A1 cells with BFA and blotted p53 and PrP expression. We found that BFA treatment reduced the level of p53 in BxPC-3 cells (Fig. 4A). However, BFA treatment of BxPC-3 cells significantly enhanced PrP expression (Fig. 4A). Although we did not detect p53 expression in H1299 and SPC-A1 cells, we detected enhanced PrP expression when those cells were treated with BFA for 24 h (Fig. 4B). Thus, BFAinduced PrP expression is independent of p53.

      Figure 4.  p53 is not the transcript factor for PrP under BFA-induced ER stress. A PrP expression is not correlated with p53 in PDAC cells. PrP expression is up-regulated in BxPC-3 cells under BFA treatment. However, reduced p53 was detected in BxPC-3 cells treated with BFA. B PrP expression is not correlated with p53 in lung cancer cells. Slight up-regulation of PrP (indicated with *) or significant upregulation of PrP was detected in SPC-A1 and H1299 cells, respectively when these cells were treated with BFA. Residual p53 or no p53 was detected in these two cancer cell lines. As a positive control, p53 was detected in BxPC-3 cells treated with BFA

    • PrP is normally a GPI-anchored glycoprotein localizing on the cell surface (Stahl et al. 1987). It can be post translationally modified on either one of the two glycosylation sites or both glycosylation sites (Rogers et al. 1990), and complex type N-linked glycans are added inside the Golgi apparatus (Lawson et al. 2005). BFA blocks secretory proteins trafficking from ER to the Golgi apparatus. Thus PrP from BFA-treated cells shall not be modified with the complex type N-linked glycans. In fact, we observed an increased motility of PrP in BFA treated BxPC-3 and lung cancer cells (Fig. 2B). To confirm that those PrP from BFA treated PDAC cells are altered in N-linked glycosylation but are not due to other post translational modifications, we treated the cell lysates of BxPC-3, H1299, and SPC-A1 cells with PNGase F, which cleaves all types of asparaginebound N-glycans as long as the oligosaccharide has the minimum length of the chitobiose core unit. We found that PNGase F-treated PrP migrated faster than the non-treated PrP (Fig. 5A). Thus, BFA treatment probably reduced complex type N-linked glycans of PrP. In addition, most PrP co-localized with BiP, a marker for ER (Fig. 5B), further confirming that PrP was retained inside the ER due to BFA treatment.

      Figure 5.  BFA treatment reduced PrP glycosylation leading to increased motility and accumulation of cytosolic PrP. A PNGase F treatment of BFA treated and non-treated cells reduced the apparent molecular weight of PrP. When comparing to non-BFA treated cells (Ctrl), PrP in BFA treated cells showed higher motility (indicated by *). After PNGase F treatment, the apparent molecular weight of PrP was further reduced (indicated by **). B Immunofluorescence staining of PrP (red) and BiP(green) showed that BFA treatment increased the levels of PrP and BiP, and the co-location of PrP and BiP

    • Cytosolic PrP has been shown to cause cellular toxicity (Ma et al. 2002; Rambold et al. 2006; Wang et al. 2009). In contrast, expression of PrP in many types of cancer cells prevents cell death (Diarra-Mehrpour et al. 2004; Roucou et al. 2005; Meslin et al. 2007). Since we found that most PrP induced by BFA was cytosolic (Fig. 5B), we then investigated if BFA treatment could result in apoptosis and whether cytosolic PrP contributes to apoptosis. We performed immunofluorescence staining of PRNP null BxPC- 3, PrP WT BxPC-3, SPC-A1, and H1299 cells treated with BFA for 24 h with propidiumiodide (PI) and Annexin V. Annexin V positive staining is for early apoptotic cells, whereas Annexin V and PI double positive staining are for late apoptotic cells. We found that BFA treatment significantly reduced the amount of PRNP null BxPC-3, WT PrP BxPC-3, and SPC-A1 cells in the petri dish (Fig. 6A), implying that those reduced cells were dead. However, we cannot exclude the possibility that BFA treatment may reduce cancer cell proliferation (Han et al. 2018). On the contrary, BFA treatment did not significantly diminish the amount of H1299 cells that adhered to the petri dish (Fig. 6A), implying that H1299 cells were resistant to BFA treatment. In addition, PRNP null BxPC-3 cells had much more apoptosis than PrP expressing BxPC-3 cells which were induced to express high levels of cytosolic PrP (Fig. 6A). Accordingly, SPC-A1, which was stimulated to express low levels of PrP, also showed more apoptosis than H1299 cells, which expressed high levels of PrP (Fig. 6A). To quantify the percentage of cell death due to BFA treatment, we performed flow cytometry assays of SPC-A1, H1299, PRNP null BxPC-3, and WT PrP expressing BxPC-3 cells after 24 h of BFA treatment. We found that BFA treatment indeed caused significantly more SPC-A1 cell death than H1299 cells (Fig. 6B). In addition, BFA treatment resulted in significantly more PRNP null BxPC-3 cell death compared to PrP expressing BxPC-3 cells (Fig. 6B). Thus, ER stress-induced apoptosis may be dependent on the levels of PrP expression. Two of the best characterized apoptosis inducers are cleaved PARP-1 and caspase-3. We then blotted the cell lysates with antibodies against caspase-3 and PARP-1 and found that BFA treated PrP null BxPC-3 had more activated caspase-3 and cleaved PARP-1 than PrP expressing BxPC-3 cells (Fig. 6C). In addition, PrP high expressing H1299 showed decreased reaction to activated caspase-3 and cleaved PARP-1 than SPC-A1 cells, which express low level of PrP (Fig. 6C). These results were consistent with the apoptosis analysis and proved that PrP could protect cells from apoptosis induced by ER stress.

      Figure 6.  BFA treatment-induced cell apoptosis might depend on expression level of PrP. A Immunofluorescence staining showed that the level of PrP might affect BFA-induced cell apoptosis. BFA treatment induced more apoptosis for BxPC-3 cells compared to DMSO control treatment (Ctrl). More apoptosis was observed for PRNP null BxPC-3 cells than WT BxPC-3 cells when treated with BFA. BFA treatment induced significantly more apoptosis for SPCA1 cells than control treatment. However, BFA treatment did not increase apoptosis of H1299 compared to DMSO control treatment. B Flow cytometry analysis showed that BFA treatment caused more apoptosis for SPC-A1 cells than for H1299 cells. Furthermore, PRNP null BxPC-3 cells had more apoptosis than PrP expressing BxPC-3 cells when treated with BFA. C Immunoblotting showed that BFA treatment resulted in more activated caspase-3 to cleave PARP-1. Furthermore, in PRNP null BxPC-3 cells, BFA treatment led to more activated caspase-3 and cleaved PARP-1

    • Herein, we provided evidence that the expression levels of PrP vary greatly among four human lung cancer cell lines, with A549 and H1299 having the highest levels, followed by H157 and then SPC-A1. The reason for this heterogenous pattern is not known. We posit that PrP contributes to lung cancer cell biology by engaging the UPR. ATF4, a pivotal UPR sensor was undetectable in untreated BxPC-3, SPC-A1, and H1299 cells. However, when treated with three different UPR-inducing agents, BFA, Thps or TM, there was a significant induction of ATF4 at transcriptional and translational levels. We found that of the three UPR inducers, BFA was by far the most potent inducer of ATF4 expression. Similar results have been observed when human neurons, astrocytes, and breast cancer MCF-7 cells were treated with BFA (Dery and LeBlanc 2017). Since BFA, but neither TM nor Thps, can transcribe and proteolytically activate luman, a non-canonical UPR transcription factor, which in turn transactivates PRNP expression (DenBoer et al. 2005; Dery and LeBlanc 2017), it is likely that the stronger PRNP expression induced by BFA is mediated by luman. Interestingly, SPC-A1 cells, which expressed the lowest PrP, had a stronger ATF4 response compared to the high PrP expressing H1299 and BxPC-3 cells.

      In the canonical PERK-eIF2α-ATF4 pathway, elevated p-eIF2α blocks translation of most genes but specifically enhances ATF4 translation (Harding et al. 2000). eIF2α was constitutively expressed in the tested cell lines in the absence of UPR stimulants. However, when the cells were stimulated with UPR inducers, the levels of p-eIF2α were up-regulated in H1299 cells but were less obvious in SPCA1 cells. Another UPR sensor, XPB-1s, is also constitutively expressed in the tested cell lines; treatment with UPR inducers does not modulate the expression levels of XPB-1.

      The UPR down-stream sensor BiP is also significantly up-regulated in both cell types when stimulated with the ER stress inducers. Again, the PrP low-expressing cell line SPC-A1 cell responded significantly more than the PrP high-expressing cell line H1299 cell. It has been reported earlier that BiP is the chaperon protein, physically associated with PrP, guiding its folding, and thus, plays a role in maintaining the quality control in the maturation of PrP (Jin et al. 2000). Higher levels of PrP in BxPC-3 and H1299 cells may have trapped BiP reducing their availability.

      The strongest evidence suggesting that PrP plays a role in the UPR is our observation that the expression of PrP is up-regulated in mRNA and in protein levels when the two cell lines where treated with the UPR inducers. As expected, the PrP protein isoforms up-regulated were quite different among the three inducing agents. Unlike BFA which promoted the accumulation of the under-glycosylated PrP, TM preferentially up-regulated the expression of un-glycosylated PrP. The lowest molecular weight bands were un-glycosylated PrP because after treatment with PNGase F to remove the N-linked glycans, all PrP species collapsed into the lowest molecular species. Interestingly, the high PrP-expressing BxPC-3 and H1299 cells appeared to express even higher levels of PrP when treated with the UPR stimulants compared to the low-PrP expressing SPCA1 cells.

      When the two lung cancer cell lines were treated with BFA, there was an increase in apoptotic cells, suggesting the ER stress had increased cell death. Interestingly, the increase in apoptotic cells was more pronounced in lowPrP expressing SPC-A1 cells compared to the high-PrP expressing H1299 cells. In addition, PRNP null BxPC-3 cells have significantly more apoptosis than wild type PrP expression BxPC-3 cells. This observation is also consistent with the immunoblotting results showing that the levels of cleaved PARP-1 and activated caspase-3 were also higher in SPC-A1 cells or PRNP null BxPC-3 cells. Collectively, these findings add credence to our interpretation that PrP has a protective function in UPR and apoptotic cell dead. Persistent ER stress can cause cancer cell death (Clarke et al. 2014). However, cancer cells also harness ER stress for their own benefits (Kaufman 1999). To take advantage of ER stress, cancer cells must implement mechanism(s) to prevent ER stress-induced cell death. This is probably one reason that the expression of PrP is up-regulated in many different human cancers.

      In summary, we have provided strong evidence that the levels of PrP might contribute to cancer cells biology by engaging the UPR. Most importantly, cells with a lower PrP level have a higher level of UPR than cells with higher PrP levels. It will be important to further these studies with additional cell lines. Nonetheless, our study supports the hypothesis that the role PrP plays in tumor biology is cellcontext dependent.

    • This work is supported by the Strategic Priority Research Program A of the Chinese Academy of Sciences (XDA12010309), by the National Natural Science Foundation of China (31670170 and 31270209), by the National Key R & D program of China (2018YFA0507201), and by the National Basic Research Priorities Program of China (2013CB911102) from the Ministry of Science and Technology of China. We thank the Core Facility and Technical Support of Wuhan Institute of Virology for technique support in confocal microscopy (Dr. Ding Gao) and flow cytometry (Ms. Juan Min).

    • ZXG, MP and CYL designed the experiment. ZXG, MP, LC performed the experiments. ZXG, MP, LC, XWY, HL, RS, GRW, LLC, QBS analyzed the data. ZXG and CYL wrote the paper. All authors read and approved the final manuscript.

    • The authors declare that they have no conflict of interest.

    • This article does not contain any studies with human or animal subjects performed by any of the authors.

    • This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

    • Table S1.  The primers used for quantitative PCR

    Figure (6)  Table (1) Reference (52) Relative (20)



    DownLoad:  Full-Size Img  PowerPoint